GlassScriptPhysician profile
Vernon C Johnson
NPI 1639228992
$5,540.62
in general payments reported to CMS, 2019-2025
36 companies · $1,755 in 2025
The $1,755 reported for 2025 was more than what 92% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,440 · 2020: $628 · 2021: $603 · 2022: $38.41 · 2023: $470 · 2024: $607 · 2025: $1,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,831.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $702.27 | 2019-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $555.72 | 2020-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $455.47 | 2024-2025 | Cobenfy |
| Allergan, INC. | $406.48 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $364.02 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $340.26 | 2019-2021 | |
| Corium, LLC | $282.85 | 2024-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $256.45 | 2023-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $252.53 | 2019-2025 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $245.06 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $184.20 | 2019-2022 | |
| Abbvie INC. | $164.43 | 2021-2025 | |
| Noven Therapeutics, LLC | $127.76 | 2020-2025 | Xelstrym, Secuado |
| Teva Pharmaceuticals USA, INC. | $111.89 | 2020-2025 | Uzedy |
| Avanir Pharmaceuticals, INC. | $108.97 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $91.12 | 2020-2021 | |
| Axsome Therapeutics, INC. | $78.80 | 2024-2025 | Auvelity |
| Shire North American Group INC | $75.09 | 2019 | |
| Adlon Therapeutics L.P. | $74.09 | 2020-2021 | |
| Livanova USA, INC. | $73.75 | 2024-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Brainsway USA INC | $65.29 | 2025 | |
| Neos Therapeutics, LP | $55.06 | 2019-2025 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $54.56 | 2019-2021 | |
| Almatica Pharma LLC | $53.72 | 2023-2024 | Loreev Xr |
| Lundbeck LLC | $52.78 | 2020-2021 | |
| Alkermes, INC. | $46.14 | 2022-2025 | Vivitrol |
| Arbor Pharmaceuticals, INC. | $40.99 | 2019 | |
| Bausch Health US, LLC | $40.38 | 2021-2025 | Aplenzin, Wellbutrin |
| Jazz Pharmaceuticals INC. | $38.13 | 2020-2021 | |
| Ge Healthcare | $36.44 | 2019 | |
| Tempus Ai, INC | $26.14 | 2024 | |
| Neuronetics, INC. | $19.38 | 2023 | Neurostar Tms Therapy System |
| Indivior INC. | $17.18 | 2023 | Sublocade |
| Collegium Pharmaceutical, INC. | $15.28 | 2025 | Jornay Pm |
| Owp Pharmaceuticals, INC. | $14.93 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vernon Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.